How should Temazepam be used in an older adult with insomnia and potential comorbidities like substance abuse history or impaired renal/hepatic function?

Temazepam Use in Older Adults: Critical Guidance

Temazepam Should Be Avoided in Older Adults with Insomnia

The American Geriatrics Society explicitly recommends against using benzodiazepines, including temazepam, in older adults due to unacceptable risks of dependency, falls, cognitive impairment, respiratory depression, and increased dementia risk. 1

---

Why Temazepam is Problematic in Older Adults

Dementia Risk

• Observational data demonstrates that benzodiazepines are associated with dementia, with the greatest effect seen with higher-dose hypnotics and benzodiazepines with half-lives exceeding 24 hours 2
• This risk persists even with intermediate-acting agents like temazepam 1

Falls and Cognitive Impairment

• The FDA label warns that temazepam causes drowsiness and decreased consciousness, placing elderly patients at substantially higher risk of falls 3
• The risk of oversedation, dizziness, confusion, and ataxia increases substantially with benzodiazepines in elderly and debilitated patients 3

Complex Sleep Behaviors

• The FDA has documented reports of sleep-driving, preparing food, making phone calls, and having sex while not fully awake, often with complete amnesia for these events 3
• These dangerous behaviors are more likely when temazepam is combined with alcohol or other CNS depressants 3

---

Special Populations Requiring Extra Caution

Substance Abuse History

• The FDA label explicitly states that temazepam is a federal controlled substance (C-IV) with risks of abuse, misuse, and addiction that can lead to overdose, coma, and death 3
• Patients with a history of alcohol or drug abuse/dependence are at higher risk for developing opioid use disorder and should be identified before prescribing 2
• Physical dependence can develop even when taking temazepam as prescribed, and abrupt discontinuation can cause life-threatening withdrawal reactions including seizures, severe mental changes, and suicidal thoughts 3

Renal or Hepatic Impairment

• The FDA label specifies that usual precautions should be observed in patients with impaired renal or hepatic function 3
• Reduced renal or hepatic function results in greater peak effect, longer duration of action, and a smaller therapeutic window between safe dosages and those associated with respiratory depression and overdose 2
• Dose selection for elderly patients should start at the low end (7.5 mg), reflecting the greater frequency of decreased hepatic, renal, or cardiac function 3

Respiratory Compromise

• Patients with chronic pulmonary insufficiency require special caution when prescribed temazepam 3
• Opioid therapy (which may be coprescribed) can decrease respiratory drive and worsen sleep apnea, and concurrent benzodiazepine use was found in 31-61% of fatal overdose deaths 2

---

Recommended Alternative: Low-Dose Doxepin

Low-dose doxepin (3-6 mg) is the most appropriate medication for sleep maintenance insomnia in older adults, with a favorable efficacy and safety profile. 1

Why Doxepin is Superior

• Low-dose doxepin has demonstrated improvement in Insomnia Severity Index scores, sleep latency, total sleep time, and sleep quality in older adults with low to moderate-strength evidence 2, 1
• It does not have the black box warnings or significant safety concerns associated with benzodiazepines 1
• Adverse effects and study withdrawals did not significantly differ between doxepin and placebo in trials lasting 4-12 weeks 2

Other Acceptable Alternatives

• Ramelteon 8 mg is appropriate for difficulty falling asleep, with minimal adverse effects and no dependency risk 1
• Suvorexant (starting at 10 mg in elderly) improves sleep maintenance with only mild side effects 1

---

If Temazepam Must Be Used: Strict Protocols

Dosing Requirements

• Start with 7.5 mg (not 15 mg or 30 mg) in elderly patients to minimize risks 3
• Research shows that 7.5 mg temazepam is effective in elderly subjects with short-term use and has a minimum of adverse effects 4
• The 7.5 mg dose produced significant improvement in total wake time (100 vs. 145 minutes at baseline) without major CNS or behavioral adverse effects 4

Duration Limits

• Limit to 7-10 days maximum for acute insomnia 3
• The American Academy of Sleep Medicine recommends limiting pharmacotherapy to short-term use, typically less than 4 weeks 1
• Efficacy beyond 2 weeks is not established per FDA labeling 3

Mandatory Monitoring

• Screen for concurrent opioid use, as the FDA has a black box warning about potentially fatal respiratory depression when combining opioids with benzodiazepines 2, 3
• Assess for sleep-driving or other complex behaviors at each follow-up; if these occur, discontinue temazepam immediately 3
• Monitor for withdrawal symptoms if discontinuing after more than a few days of use, as abrupt cessation can cause seizures and life-threatening reactions 3

Absolute Contraindications

• Do not prescribe with alcohol or other CNS depressants without close supervision 3
• Avoid in patients with known substance abuse history unless no alternatives exist 3
• Do not use in pregnancy (Category X) or breastfeeding 3

---

Critical Pitfalls to Avoid

• Never prescribe temazepam as first-line therapy in older adults when low-dose doxepin or ramelteon are available 1
• Never combine with opioids without explicit awareness of fatal respiratory depression risk and close monitoring 2, 3
• Never stop abruptly after more than a few days of use; taper slowly to prevent life-threatening withdrawal 3
• Never prescribe 15 mg or 30 mg as initial doses in elderly patients; always start with 7.5 mg 3
• Never ignore reports of sleep-driving or complex behaviors; these mandate immediate discontinuation 3

---

First-Line Approach: Non-Pharmacological

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be the initial treatment for chronic insomnia in elderly patients before considering any medication. 1

• CBT-I has demonstrated superior long-term outcomes compared to pharmacotherapy with fewer adverse effects 1
• Combining behavioral and pharmacologic therapy provides better outcomes than either modality alone, with medications providing short-term relief and CBT-I providing longer-term sustained benefit 1